Marked hypertriglyceridemia upon treatment with etanercept

Joint Bone Spine

Volumn 76, Issue 5, 2009, Pages 570-571

  Haroon, Muhammad ^a   Devlin, Joe ^a  

^a WATERFORD REGIONAL HOSPITAL   (Ireland)

Author keywords

Anti TNF agent; Etanercept; Hypertriglyceridemia; Statin

Indexed keywords

ETANERCEPT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; ROSUVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALCOHOL CONSUMPTION; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FOLLOW UP; HUMAN; HYPERTRIGLYCERIDEMIA; LETTER; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MALE; NEUTROPENIA; PSORIATIC ARTHRITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CHOLESTEROL; HUMANS; HYPERTRIGLYCERIDEMIA; IMMUNOGLOBULIN G; LIPOPROTEINS, HDL; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; TRIGLYCERIDES;

EID: 70449532376     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.01.002     Document Type: Letter

References (12)

1. Sattar N., McCarey D.W., Capell H., et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108 (2003) 2957-2963
2. Allanore Y., Kahan A., Sellam J., et al. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 365 (2006) 143-148
3. Popa C., van den Hoogen F.H., Radstake T.R., et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 66 (2007) 1503-1507
4. Popa C., Netea M.G., Radstake T., et al. Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 64 (2005) 303-305
5. Garcês S.P., Parreira Santos M.J., Vinagre F.M.R., et al. Anti-tumour necrosis factor agents and lipid profile: a class effect?. Ann Rheum Dis 67 (2008) 895-896
6. Scheryer S.A., Vick C.M., and LeBouef R.C. Loss of lymphotoxin-α but not tumor necrosis factor-α reduces atherosclerosis in mice. J Biol Chem 277 (2002) 12364-12368
7. Vahlquist C., Michaelsson G., and Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 67 (1987) 12-15
8. Uyanik B.S., Ari Z., Onur E., et al. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 40 (2002) 65-68
9. Skoczyñska A.H., Turczyn B., Barancewicz-Losek M., et al. High-density lipoprotein cholesterol in patients with psoriatic arthritis. J Eur Acad Dermatol Venereol 17 (2003) 362-363
10. Rocha-Pereira P., Santos-Silva A., Rebelo I., et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 303 (2001) 33-39
11. Antoniou C., Dessinioti C., Katsambas A., et al. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol 156 (2007) 1090-1091
12. Stinco G., Piccirillo F., and Patrone P. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol 157 (2007) 1273-1274